On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Vantage Drilling Company (NYSEMKT:VTG), Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), Navios Maritime Holdings Inc. (NYSE:NM), Wynn Resorts Ltd. (NASDAQ:WYNN)
Latest NEWS regarding these Stocks are depicted underneath:
Vantage Drilling Company (NYSEMKT:VTG)
Formerly on March 6, Vantage Drilling Corporation (VTG), stated net revenue for the three months ended December 31, 2014 of $12.6 million or $0.04 per diluted share as contrast to earnings of $30.3 million or $.09 per diluted share for the three months ended December 31, 2013. The three months ended December 31, 2014 comprises a gain on the early retirement of debt of about $4.2 million.
The $4.2 million gain on the early retirement of debt represents the discount to the face value of debt that we purchased in the open market, net of writing off deferred financing costs. The total debt retirement for the quarter, counting planned maturities and open market purchase of debt, totaled about $60.6 million at face value.
For the twelve months ended December 31, 2014, Vantage reports record net revenue of about $38.3 million or $.12 per diluted share, not including net gains from the early retirement of debt of about $3.8 million as contrast to net revenue of about $16.5 million or $.05 per diluted share, not including about $98.3 million of charges for the early retirement of debt. Counting the gains and losses associated with the early retirement of debt, for the twelve months ended December 31, 2014, Vantage reports net revenue of $42.0 million or $.14 per diluted as contrast to a net loss of $81.8 million or ($.27) per diluted share for the same period in 2013.
During 2014, the total debt retirement, counting planned maturities, discretionary Term Loan payments and open market purchases, was about $199.7 million at face value. In connection with our discretionary Term Loan payments and open market purchases, we recognized a net gain on the early retirement of debt of about $3.8 million.
Paul Bragg, Chairman and Chief Executive Officer, commented, “We are happy to declare Vantage accomplished 2014 with record proceeds, EBITDA and net revenue for the year. With strong cash flows, we were able to exceed our targeted debt retirement aim and strengthen the balance sheet.”
Vantage Drilling Corporation, through its auxiliaries, provides offshore contract drilling services in the United States and internationally. It offers drilling units, related equipment, and work crews under contract to drill oil and natural gas wells.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Formerly on March 11, Bellicum Pharmaceuticals, Inc. (BLCM), a clinical stage biopharmaceutical corporation focused on discovering and developing novel cellular immunotherapies, stated financial results for the fourth quarter and full year ended December 31, 2014, and offered an update on the Corporation’s recent progress.
Program Updates:
- Accomplished enrollment of the initial phase of a Phase 1/2 clinical trial of BPX-501 in the HSCT setting: The Phase 1 cohorts of this trial enrolled an equal number of patients with blood cancers and non-malignant genetic diseases such as Fanconi’s syndrome or severe combined immunodeficiency (SCID). This open label dose escalation study in pediatric patients is evaluating whether genetically engineered BPX-501 T cells from haplo-identical donors administered following a T-depleted HSCT are safe and can enhance immune reconstitution. BPX-501 contains the CaspaCIDe® safety switch, giving doctors the ability to eliminate the T cells should they cause Graft-as compared to-host disease.
- Advanced our CAR-T and TCR cell therapy programs: Bellicum continued to advance its pipeline of next-generation CAR-T and TCR controllable cell therapies with a TCR product candidate predictable to enter a Phase 1/2 clinical trial by the end of 2015. BPX-701, a TCR-based therapy that incorporates the CaspaCIDe® safety switch, is initially being developed to treat PRAME-expressing sarcomas and neuroblastomas.
- Began enrolling the third patient cohort of the Phase 1 clinical trial of BPX-201: BPX-201 is a dendritic cell vaccine using DeCIDe® technology for patients with metastatic castrate-resistant prostate cancer. Bellicum is presently preparing for further development of BPX-201 in combination with a checkpoint inhibitor.
- Presentation at the 2014 ASH meeting: Bellicum presented a poster with information demonstrating preclinical proof of principle that inducible MyD88/CD40 allows rimiducid-mediated co-stimulation to control activation and proliferation of CAR-T cells.
- Rimiducid recognized as first in new drug class: The World Health Organization’s (WHO) International Nonproprietary Name (INN) Expert Group has published the recommended nonproprietary name “rimiducid” for the small molecule drug formerly known as AP1903, establishing it as the first of a new drug class assigned the unique suffix “-ducid.” Rimiducid is the lead small molecule activator for Bellicum’s platform of Chemical Induction of Dimerization (CID)-controllable molecular switches.
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical corporation, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer.
Navios Maritime Holdings Inc. (NYSE:NM)
Navios Maritime Holdings Inc. (NM), DHT Holdings (NYSE: DHT), Euronav (NYSE: EURN), Dorian LPG (NYSE: LPG), Gaslog (NYSE: GLOG), Safe Bulkers (NYSE: SB), Seaspan Corporation (NYSE: SSW), Scorpio Tankers (NYSE: STNG), Star Bulk Carriers (NASDAQ: SBLK) and Tsakos Energy Navigation, Ltd. (NYSE: TNP) are among the shipping companies participating at Capital Link’s 9th Annual International Shipping & Offshore Forum taking place on Monday, March 23, 2015 at the Metropolitan Club in New York City.
Navios Maritime Holdings Inc. operates as a seaborne shipping and logistics corporation. It focuses on the transportation and transshipment of dry bulk commodities, counting iron ore, coal, fertilizers, and grains.
Wynn Resorts Ltd. (NASDAQ:WYNN)
On March 16, Wynn Resorts Ltd. (WYNN), declared that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with Wynn Resorts’ Annual Meeting of Stockholders, which is planned to be held on April 24, 2015.
Wynn Resorts, Limited, together with its auxiliaries, develops, owns, and operates destination casino resorts. It operates in two segments, Macau Operations and Las Vegas Operations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
